News Releases and Coverage

Neovasc Tiara(TM) Progress Highlighted at PCR London Valves 2019 (SPH)

St. Paul's Hospital (Photo credit: Big News Network)
St. Paul's Hospital (Photo credit: Big News Network)

Vancouver, British Columbia–(Newsfile Corp. – November 19, 2019) – Neovasc, Inc. (NASDAQ: NVCN) (TSX: NVCN) (“Neovasc” or the “Company”), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that its transfemoral trans-septal (“TF/TS”) Tiara™ (“Tiara”) System was featured today in a tutorial session at the PCR London Valves 2019 meeting, which is taking place November 17-19 in London.

Anson Cheung, MD, Clinical Professor of Surgery and Director of Cardiac Transplant of British Columbia, and Principal Investigator for the Tiara Early Feasibility Study at St. Paul’s Hospital, Vancouver, BC, provided an update on the Tiara program as part of “Rapid fire – Latest updates from the world of TMVR,” a session focusing on early clinical outcomes of patients undergoing transcatheter mitral valve replacement and potential future device solutions.

Click here to read the full story in Yahoo Finance.

Give us your comments and story ideas

X